$TMO

CASPER MARC N sold $5.7M of TMO

CASPER MARC N (Chairman & CEO) sold 10,000 shares of THERMO FISHER SCIENTIFIC INC. (TMO) at an average of $574.47 ($571.05–$579.90, $5.74M total) across 9 trades on 2026-08-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · CASPER MARC N
Published Aug 7, 2026, 9:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 7, 2026, 9:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TMO
Neutral
medium confidence
Mentioned
$TMO
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TMONeutralLow
01

Why it matters

The newest fact is the specific open-market sale details (10,000 shares across 9 trades, $5.74M total) and confirmation that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

This provides a fresh, primary-source datapoint on insider selling, but the 10b5-1 designation typically limits interpretive value for price action.

03

What to watch

Traders may also consider whether the insider’s remaining holdings (123,925 shares after sale) and any prior sale cadence suggest a planned schedule rather than new information.

Relevance 5/10Novelty 5/10Timing: today’s SEC Form 4 filing (filed 2026-08-07)

Background

The article is an SEC Form 4 insider transaction disclosure for Thermo Fisher Scientific, reported by its Chairman & CEO.

Company-level read

Ticker impact

$TMONeutralMedium confidence
Context

Thermo Fisher CEO/C chairman Casper Marc N sold 10,000 shares in an open-market transaction totaling about $5.74M at $571.05–$579.90.

Expected impact

Likely limited near-term impact; any reaction is typically muted when the filing states a 10b5-1 plan.

Evidence & confidence

The filing provides transaction size, price range, and confirms a pre-arranged 10b5-1 plan, which traders often discount versus discretionary selling.

Market effects

Minimal; this is company-specific insider activity with no stated operational or regulatory change.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect routine liquidity needs rather than bearish expectations.

Key entities

  • THERMO FISHER SCIENTIFIC INC.

    Subject of the Form 4 insider transaction disclosure.

  • CASPER MARC N

    Chairman & CEO who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TMOHighAI 8/10

Thermo Fisher Q3 Revenue Hits $12.14 Billion as Shares Touch Record $705 — BigGo Finance

Thermo Fisher Scientific reported Q3 revenue of $12.14B, up 9% YoY, with shares reaching a record $705.79. Analysts raised target prices. Growth was driven by new products and AI initiatives, including a collaboration with Nvidia. The company also integrated Clario to expand clinical services. Revenue sources include lab consumables (52%) and high-growth areas like mass spectrometry and sequencing. AI and clinical data services are key focus areas for future growth.

$COFHighAI 8/10

Company News for Oct 22, 2026

Capital One (COF) shares rose 2.5% after reporting Q3 2026 adjusted earnings of $6.69 per share, beating estimates. Bank OZK (OZK) shares gained 4.2% with $1.50 per share earnings, surpassing expectations. Thermo Fisher (TMO) shares increased 1% with $6.68 per share earnings, exceeding estimates. Danaher (DHR) shares climbed 4.3% with $2.11 per share earnings, outpacing forecasts.

$TMOHighAI 8/10

Thermo Fisher Scientific Hits $12.14 Billion in Q3 Revenue as Innovation Fuels Double-Digit Earnings Growth

Thermo Fisher Scientific reported Q3 2026 revenue of $12.14 billion, up 9% YoY, with organic growth of 6%. GAAP EPS rose 9% to $4.64, while adjusted EPS increased 15% to $6.68. The company attributed growth to innovation and strategic initiatives, including new product launches and partnerships. According to CEO Marc Casper, the results reflect strong execution and a proven growth strategy.